# 15TH ANNUAL WINTER HEMATOLOGY CONFERENCE

## JANUARY 23 2027

**MARRIOTT VIRGINIA BEACH OCEANFRONT**
4201 Atlantic Avenue
Virginia Beach, VA 23451



Virginia Oncology Associates

Macon & Joan Brock Virginia Health Sciences at Old Dominion University

## 15th Annual Winter Hematology Conference | Saturday, January 23, 2027

# MARRIOTT VIRGINIA BEACH OCEANFRONT

**4201 Atlantic Avenue | Virginia Beach, Virginia 23451**

Macon & Joan Brock Virginia Health Sciences at Old Dominion University Continuing Medical Education and Virginia Oncology Associates would like to invite you to attend the 15th Annual Winter Hematology Conference designated for a maximum of 6 *AMA PRA Category 1 Credits*™.

**TARGET AUDIENCE:** Internists, Family Medicine Physicians, Medical Oncologists, Hematologists, Pathologists, Vascular Surgeons, Nurse Practitioners, Physician Assistants, Nurses, and other interested healthcare providers.

## AGENDA

| | |
|---|---|
| **7:00 AM** | **Registration, Breakfast, Networking, Exhibit Visits** |
| **7:50 AM** | **Welcome & Introduction**<br>*Burton Alexander, III, MD* |
| **8:00 AM** | **Everyday Management of Lower & Higher Risk Myelodysplastic Neoplasms**<br>*Harry P. Erba, MD* |
| **9:00 AM** | **Diagnosis and Management of Refractory Immune Thrombocytopenia (ITP)**<br>*Sandhya R. Panch, MD* |
| **9:30 AM** | **Diagnosis and Management of Autoimmune Hemolytic Anemia (AIHA)**<br>*Sandhya R. Panch, MD* |
| **10:00 AM** | **Snack Break & Exhibit Visits** |
| **10:30 AM** | **Hereditary Hemochromatosis Management**<br>*Santosh L. Saraf, MD* |
| **11:00 AM** | **Evolving Landscape of Diffuse Large B-Cell Lymphoma**<br>*Craig A. Portell, MD* |
| **11:30 AM** | **Follicular Lymphoma: The Definition of the Art of Medicine**<br>*Craig A. Portell, MD* |
| **12:00 PM** | **Lunch & Exhibit Visits** |
| **1:00 PM** | **Choosing Wisely:**<br>**Venous thromboembolism (VTE) Prevention and Management**<br>*Hillary S. Maitland, MD* |
| **2:00 PM** | **Update on Cold Agglutinin Disease**<br>*Catherine M. Broome, MD* |
| **2:30 PM** | **Therapeutic Evolution in Mantle Cell Lymphoma (MCL):**<br>**Treatment Approaches in 2027**<br>*Michael E. Williams, MD* |
| **3:30 PM** | **Adjourn** |

**ACCREDITATION:** This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Macon & Joan Brock Virginia Health Sciences at Old Dominion University and Virginia Oncology Associates. Macon & Joan Brock Virginia Health Sciences at Old Dominion University is accredited by the ACCME to provide continuing medical education for physicians.

**CREDIT DESIGNATION:** Macon & Joan Brock Virginia Health Sciences at Old Dominion University designates this live activity for a maximum of 6 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**SPECIAL SERVICES:** If special arrangements are required for an individual with a disability to attend this conference, contact the CME office at (757) 446-6140 at least 15 days prior to the conference.

# LEARNING OBJECTIVES

- Evaluate the efficacy of treatment options to improve blood counts in lower risk myelodysplastic neoplasms.
- Identify treatment options to improve overall survival in higher risk myelodysplastic neoplasms.
- Describe the pathophysiology and diagnostic aspects of ITP. Elucidate management aspects of ITP.
- Describe the pathophysiology and diagnostic aspects of AIHA. Elucidate management aspects of AIHA.
- Identify when to initiate and stop therapeutic phlebotomy for hereditary hemochromatosis syndromes.
- Determine when and what clinical and laboratory values to monitor in patients with hereditary hemochromatosis.
- Evaluate the frontline therapies for diffuse large B-cell lymphoma and how to decide/utilize them.
- Explain the predictive value in minimal residual disease testing and how to use them.
- Determine when and if treatment is indicated for frontline therapy.
- Describe novel agents and when to utilize them.
- Identify which patients require further evaluation for a hypercoagulable state.
- Choose the best VTE prophylaxis strategy for hospitalized patients
- Identify the diagnostic pathway for cold agglutinin disease.
- Manage cold agglutinin disease with new treatment modalities.
- Identify risk-adapted treatment approaches for newly diagnosed patients with MCL.
- Describe the emerging role for CAR T-cell therapy and bispecific antibodies in relapsed and high-risk MCL.

# FACULTY


***COURSE DIRECTOR:***
***Burton Alexander, III, MD***
*Virginia Oncology Associates*

***Catherine M. Broome, MD***
Department of Medicine
MedStar/Georgetown University
Washington, DC

***Harry P. Erba, MD, PhD***
Professor of Medicine
Director of the Leukemia Program
Duke University School of Medicine and the
Duke Cancer Institute
Durham, NC

***Hillary S. Maitland, MD, MS***
Associate Professor of Medicine
University of Virginia
Division of Hematology/Oncology
Charlottesville, VA

***Sandhya R. Panch, MD, MPH***
Associate Professor of Medicine
Division of Hematology
University of Washington
Director of Transfusion
Fred Hutch Cancer Center
Adjunct Associate Professor
Department of Laboratory Medicine & Pathology
University of Washington
Seattle, WA

***Craig A. Portell, MD***
Professor of Medicine
Section Head—Hematologic Malignancies
Medical Director of Lymphoma/CLL/Myeloma
Clinical Research Team
Division of Hematology/Oncology
University of Virginia
Charlottesville, VA

***Santosh L. Saraf, MD***
A. Tom Petropulos Professor
Director, Sickle Cell Center
Medical Director, CCTS Clinical Research Center
Division of Hematology & Oncology
University of Illinois Chicago
Chicago, IL

***Michael E. Williams, MD, ScM***
Byrd S. Leavell Professor of Medicine, Emeritus
Hematology/Oncology Division
UVA Comprehensive Cancer Center
University of Virginia School of Medicine
Charlottesville, VA

**Macon & Joan Brock Virginia Health Sciences at Old Dominion University**
Office of Continuing Medical Education
PO Box 1980
Norfolk, VA 23501-1980

NON-PROFIT ORG.
U.S. POSTAGE
**PAID**
NORFOLK, VA
PERMIT NO. 22

## REGISTRATION INFORMATION

**REGISTRATION FEE:** $45 for all participants
**REGISTRATION DEADLINE:** Friday, January 15, 2027
**ONLINE:** Register online at **https://bit.ly/VOA27HemConf**
or scan the QR code. Credit Card Only.
**FOR MORE INFORMATION, CONTACT THE CME OFFICE**
Call (757) 446-6140 or email CME@ODU.EDU

## ACCOMMODATIONS

**HOTEL:**
Marriott Virginia Beach Oceanfront
4201 Atlantic Avenue, Virginia Beach, VA 23451
Reservations at **https://book.passkey.com/e/51360125**
or call Marriott Central Reservation at 1-888-236-2427
**Group Name:** VA Oncology
**Group Code:** VOM
**Event Date:** January 23, 2027
**Rate:** $160 (*Hotel room discount available for Friday night. Cut off date is December 23, 2026.*)

**PARKING:** On-Site parking will be covered by VOA. Please bring your ticket to the registration desk. Valet service will not be covered.